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Advancements in the development on new liquid
embolic agents for use in therapeutic
embolisation
Jasmine Lord,a Hugh Britton,b Sebastian G. Spain *a and Andrew L. Lewisb
Liquid formulations have a well-established role in therapeutic embolisation of blood vessels with the
widespread use of cyanoacrylate glues, precipitating polymer suspensions, sclerosing agents and viscous
emulsions of oil and chemotherapeutic agents. There is currently an emerging market for next generation
liquid embolics which aim to address some of the short-comings of the currently used products. These
next generation systems use varying chemistries in their approach to formulate new systems including
polymerising, precipitating and phase-transitioning mechanisms to form solidified masses in situ within the
vasculature. Some of these emerging technologies have been developed to possess improved imaging
properties such as inherent radiopacity, rather than relying on having to mixing with radiopaque materials
such as tantalum powder and reduction of X-ray imaging artefacts (streaking). Others offer solvent-free
formulations which gel on contact with blood thereby allowing precise control over gel formation
during the embolisation process without the use of potentially toxic solvents. In this review, we discuss
the role of liquid agents in therapeutic embolisation and the potential of emerging technologies under
development for use in the next generation of embolics.
1. Introduction
Therapeutic embolisation is a well-established treatment with a
wide variety of embolic devices available on the market including
coils, balloons and particles. The range of commercially avail-
able embolic agents represents the breadth of embolisation
treatments that are performed and highlights the need to tailor
each procedure on a case-by-case basis, dependent upon the size
and extent of vasculature to be blocked and the need to block
more proximal or distal to the position of the catheter through
which they are delivered. There may, however, be complications
with these techniques, some dependent upon the skill and
experience of the physician and others that are influenced by
the properties of the embolic agents. For example, microcatheter
blocking1 and off-target embolisations2 are the primary issues
faced and can be a result of both of human error and poor
handling characteristics of the embolic agent. Liquid embolic
materials are no different in this respect but the ability to solidify
in situ offers alternative characteristics to the more commonly
used particulate systems that, although delivered in a liquid
carrier, are preformed particles that are not colloidally stable,
and provides additional tools and capabilities to the treating
physician for therapeutic embolisation applications.
Those liquid embolic agents that transition in phase func-
tion by solidification in situ when injected into the vasculature,
changing from liquid to solid form by processes such as
precipitation or polymerisation. The in situ formation of a gel
enables the liquid formulation to be easily delivered using a
microcatheter provided that the liquid materials are of an
appropriate viscosity when in their solution state and circum-
vents the problem of microcatheter blockage due to aggregation
of particles or microspheres.
Once the liquid undergoes a sol–gel transition, it provides an
added advantage over preformedmaterials, such as coils, in that the
resulting gelling mass can mould itself to fill the geometry of the
vessel into which it is injected along with any irregularities. Hence,
the final gel form is unique and conforms ideally to the contours of
the vessel being treated. It acts to fully occlude the vessel and does
not rely on thrombus formation to complete the occlusion. There-
fore, liquid embolic materials are advantageous in patients with
coagulopathies or patients receiving anti-coagulation therapy in
which their ability to form blood clots is impaired.3,4 Furthermore,
the formation of a single solid mass of embolic material at the
treatment site also provides the advantage of a reduced risk of
fragment migration once implanted. This is often a concern with
embolic materials, such as particulates, which pose the risk of
dislodging once implanted leading to off-target embolisation.
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2. Established liquid embolics
Excluding sclerosants that chemically damage the vessel wall in
order to induce its collapse, there are currently three main
liquid agents used for embolisation procedures in the clinic;
cyanoacrylate glues (such as Trufills, Codman), ethylene-vinyl
alcohol (EVA) copolymer solution (such as Onyxs, Medtronic)
and iodinated poppyseed oil (Lipiodols, Guerbet). Lipiodols
has been used for many years as an imaging agent and is used
off-label in the treatment of heptatocellular carcinoma (HCC),
where is it mixed with aqueous chemotherapy solutions to
create a viscous emulsion that aids in temporarily reducing
blood flow.5 It does not however, cause a permanent stasis of
flow in the vessel. The cyanoacrylate glues and EVA solutions
are used in a much wider range of vascular conditions but
again, often in an off-label setting, including the treatment
of arteriovenous malformations (AVMs),6 gastrointestinal
bleeding7 and aneurysms.8 These liquid embolics are primarily
delivered using narrow lumen microcatheters with hydrophilic
coatings that provide lubricity and reduce interactions with the
inner lumen to aid the delivery of the liquids as they pass
through the microcatheter during injection. In the case of EVA
solutions that are formulated in the organic solvent dimethyl
sulfoxide (DMSO), the microcatheter must be made of chemi-
cally inert materials to avoid being softened or dissolved by this
powerful solvent. Balloon microcatheters are frequently utilised
in the delivery of liquid embolics due to their ability to reduce
blood flow during injection of the solidifying liquid thereby
providing more control over the delivery process. The balloon
is inflated behind the distal tip of the microcatheter in order
to prevent blood flow past the tip, allowing the precipitation
process to occur at the tip of the catheter as the solution mixes
with the blood, reducing the risk of material fragmentation
and stringing.
2.1. Cyanoacrylate glues
There are a number of glues commercially available including
TruFills (Codman), Histoacryls (B. Braun) and Glubrans 2
(GEM) amongst many others. A recent entry to the market has
been Sapheon VenaSealt (Medtronic Inc.) specifically indi-
cated for the closure of the Greater Saphenous Vein (GSV) to
treat varicose veins. The glue formulations are predominantly
based on the monomer N-butyl-2-cyanoacrylate (nBCA), a deri-
vative of Supergluet. Other cyanoacrylate derivatives have been
developed and tested in which the aliphatic side chain has been
varied which affects rate of polymerisation and physical proper-
ties of the resulting polymer mass. There were some reports
that the N-butyl version caused sarcomas and hence the iso-
butyl derivative has become favoured and most commonly
used.9,10 On entering blood vessels, the nBCA monomer rapidly
polymerises under the ionic conditions found in blood to form
an embolus within the vasculature (Fig. 1). Care must be taken
during the preparation of the glue to prevent premature poly-
merisation of the monomer on contact with ionic solutions.
Prior to the injection of glue, the microcatheter must be flushed
with a non-ionic 5% dextrose solution in order to prevent
polymerisation within the microcatheter which could result in
microcatheter blockage. Delivery of glue through pre-flushed
microcatheters ensures that the glue rapidly polymerises on
contact with blood upon exiting the tip of the microcatheter at
the delivery site. The fast rate of polymerisation is particularly
Fig. 1 In situ polymerisation of N-butyl-2-cyanoacrylate (nBCA). (Nu refers to a nucleophilic species, which would most commonly be water in the
case of delivery into the blood stream).
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beneficial in cases where rapid embolisation is required such
as trauma or gastrointestinal bleeding.
The low viscosity nature of the nBCA glue results in the
formation of a solid cast within the blood vessels with occlu-
sion focused distally.11 Embolisation with this system provides
permanent occlusion of the targeted vessels due to the initia-
tion of an acute inflammatory response in the blood vessel
walls and surrounding tissue. This is thought to be a conse-
quence of the polymerising species reacting with proteins and
cellular structures in the vessel wall, the local generation of
heat and potential to release toxic by-products such as formal-
dehyde during the polymerisation.10,12,13 This leads to fibrosis
of the surrounding area resulting in permanent occlusion of
the treated blood vessels.14
The rate of polymerisation can be predictably controlled by
the addition of glacial acetic acid and Lipiodols (Guerbet Llc.)
which act as polymerisation retardants.15 The addition of these
polymerisation retardants to create dilutions in the range
25–67% is recommended as a method to slow the rate of
polymerisation due to the reduced ionic contact of the glue with
blood; 67% nBCA will polymerised in around a second whereas
25% nBCA takes around 6 seconds.11 This provides greater
flexibility in the working times of the glue.16 The use of Lipiodols
in combination with glue increases the overall viscosity of the
liquid to improve control of the injection and reduce distal
embolisation. Additionally, the Lipiodols contrast agent has the
advantage of imparting radiopacity to the embolic solution
enabling the injection to be monitored by real-time fluoroscopy,
although Trufills glue kits contain both ethiodised oil and
tantalum powder if additional radiopacity is desired.
Following the delivery of glue, it is necessary to immediately
withdraw the microcatheter. This is to prevent the entrapment
of the microcatheter at the site of administration due to the
highly adhesive nature of the material.17 Gluing of the micro-
catheter in place may also occur due to excessive degrees of
reflux of the material which is dependent on the volume injected
or early polymerisation. Hence, careful attention must be made
to the preparation of the liquid embolic prior to procedure, the
delivery technique and the volume of liquid used. Intermittent
injection of the polymerising liquid embolic can result in
microcatheter blockage which requires the removal and place-
ment of a new microcatheter when this occurs.18 The occurrence
of microcatheter entrapment requires the microcatheter to be
broken to leave the distal end in place within the vasculature.19 It
is generally attempted to keep the remaining microcatheter
length as short as possible to avoid the proximal end from
blocking or rupturing nearby blood vessels. However, if this
cannot be achieved then the microcatheter is cut at the point
where it enters the artery and is then secured at the site of entry
located at either the groin if femoral access was used or the wrist
if radial access was used.20
Microcatheters with a hydrophilic coating have been shown
to demonstrate reduced adhesion towards cyanoacrylate glue.21
Additionally, microcatheters are available with detachable tips,
such as Apollot marketed by Medtronic Inc., which allow a
short section of the microcatheter tip to be safely detached and
left in place if adhesion to the embolic material were to
occur.22,23 However, the use of these microcatheters in the
clinic must be carefully considered due to the resulting higher
cost. The risk of microcatheter entrapment is largely dependent
on the operator’s proficiency and embolic material formulation
hence specially designed microcatheters offer limited benefits.
Despite the risks of microcatheter blocking and entrapment,
nBCA glue is still in widespread clinical use, particularly due to
its low cost, with interventional radiologists that are experi-
enced and proficient in its delivery.
2.2. Ethylene vinyl alcohol copolymer, Onyxs
Onyxs (Medtronic Inc.) is a liquid embolic system based on a
poly(ethylene-co-vinyl alcohol) (EVA) copolymer (Fig. 2) dis-
solved in DMSO with micronised tantalum powder added in
suspension. Prior to delivery, Onyxs must be agitated for a
minimum of 20 minutes to achieve a uniform suspension of the
DMSO polymer solution and tantalum radiopacifying agent as
the metal particles sediment quickly over time due to their
density.24 On delivery into the vasculature, the polymer
precipitates out of solution as it is diluted by the aqueous
conditions of blood which act as a non-solvent for the polymer.
The precipitation of the polymer results in the entrapment of
the suspended tantalum powder and the gradient diffusion of
DMSO from the precipitated plug. Once precipitated, Onyxs
forms a gel with a sponge-like consistency making it ideal for
use in the treatment of AVMs as the occluded vessels are soft
and easily removed by surgical methods.25,26 The tantalum
contained within the precipitated gel imparts long-term radio-
pacity to the material meaning the embolised vessels can be
easily located by X-ray imaging. The suspended tantalum
imparts a black colour to the suspension hence care must be
taken when treating sites near to the skin surface as this can
show through the skin layers and cause a tattoo-like staining
which can also be observed internally by endoscopy (Fig. 3 and 4).
In addition, it is important to be cognisant of the location of a
previously treated site when considering follow-on therapies, as
application of treatments such as radiofrequency ablation in the
vicinity of the occluded mass can induce sparking between the
metal particles.
Onyxs is marketed with a range of different viscosities
including Onyxs 18 which is 18 mPa s, Onyxs 34 which is
34 mPa s and Onyxs 500 which is 500 mPa s. The different
Onyxs formulations available allow the selection of appropriate
viscosities depending on the size and blood flow rate in the
vasculature targeted. For example, low viscosity Onyxs 18 is
suited for treatments requiring high degrees of distal penetra-
tion, such as AVMs, as the low viscosity solution can penetrate
deep into the nidus of the growth.29 Whereas, high viscosity
Onyxs 500 is better suited for embolisation of aneurysms,
Fig. 2 Chemical structure of poly(ethylene-co-vinyl alcohol).
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particularly of wide necks which are not suitable for surgical
clipping, as the high viscosity can resist potential wash-out of
the material due to the flow of blood past the aneurysm neck.30
In contrast to nBCA glue, Onyxs does not initiate any
significant inflammatory response. However, injection of the
organic solvent DMSO necessitates further patient sedation to
reduce discomfort. The solvent also penetrates through the
skin and results in an unpleasant garlic-like odour.31 Injection
of DMSO can also result in the occurrence of vasospasm, a
phenomenon in which the blood vessels suddenly constrict
causing reduced diameters and blood flow, due to the cytotoxi-
city of the solvent.32 If this occurs then the injection must be
halted until the vasospasm stops which increases the proce-
dural time and patient risks. Vasospasms can be prevented
using slow injection times33 and hence the recommended
injection rate of Onyxs is 0.16 mL min1.24 The administration
of Onyxs is requires use of specialist syringes and micro-
catheters due to degradation of the more commonly employed
versions by the DMSO solvent.32 Suitable microcatheters for
injection of the DMSO based liquid embolic include Rebart
(Medtronic Inc.), Progreats (Terumo) and Apollot (Medtronic Inc.).
This precipitating system resolves some of the issues experi-
enced with nBCA glue as Onyxs is non-adhesive in nature
and so has a reduced risk of microcatheter blockage and
entrapment.34,35 The entrapment is further reduced with the
use of the manufacturers (Medtronic Inc.) specialist DMSO-
compatible microcatheter, Apollot, with a detachable tip
which can be left in place inside the patient if the microcatheter
tip becomes entrapped in the solidified embolic plug during
the procedure. This provides a safe and effective method of
dealing with microcatheter entrapment if it occurs to reduce
patient risk of complication associated with leaving a large
length of microcatheter in place. The delivery process can
also be carried out using intermittent injections allowing the
delivery to be paused to evaluate the progress of the embolus
and then continued with further penetration of the embolus
into the vasculature. As the solution is injected through the
catheter, a small mass of polymer gel forms and adheres to the
tip, swelling as further solution is administered. A skin forms
at the solution-blood interface as the material precipitates,
forming a solution filled sac which is further expanded by the
growing mass of fresh solution exiting the catheter tip. This
causes continuous rupture of the forming skin as the embolus
continues to expand with subsequent reskinning as the freshly
exposed solution precipitates. This process has often been
described as ‘lava-like’ in nature and allows for level of control
over the procedure not possible with glue-based embolics.36
This ‘pushability’ of the material in paused increments means a
single microcatheter can be used for multiple injections during
each procedure without the need to place new microcatheters
after each injection. Once sufficient material has been delivered,
the end-point of the embolisation is determined when the
delivered liquid embolic no longer flows within the vessel due
to its solidification and is easily visualised under real-time fluoro-
scopy. Following implantation of Onyxs, the solidified embolic
material can be readily located by X-ray imaging techniques.
Fig. 3 Endoscopy after embolisation of the right gastric artery branches with Onyxs demonstrating black staining/discoloration of the mucosa in the
prepyloric region with relatively normal surrounding gastric mucosa (yellow) next to hemoclips (blue arrows). Reproduced with permission from J. Clin.
Imag. Sci. 2018, 8, 46.27
Fig. 4 Showing the tattooing of effect Onyxs 18 on an upper eyelid
pulsating mass pre-(A) and post-(B) treatment. Reproduced from
J. NeuroInt. Surg. 2018, 10, 240–244.28
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Using computed tomography (CT) imaging, which is convention-
ally used for patient follow-up, the embolic is visualised as a dense
bright white region due to the high radiopacity imparted by the
tantalum radiopacifying agent. However, due to the metallic
nature and high radiodensity of tantalum, Onyxs often exhibits
streak artefacts under X-ray imaging as a result of beam hard-
ening and scattering of the X-ray energy used during scanning
(Fig. 5).37 This imaging artefact can obscure the surrounding
anatomy of the treated vascular abnormalities and hinder further
diagnosis or monitoring of disease progression. This can also
pose difficulties in assessment of optimal embolisation or require-
ment of further treatments. For this reason, Onyx manufacturers
Ev3 recently launched a new ‘‘L’’ range of Onyx which contains
less tantalum to reduce the incidence of imaging artefacts.
2.3. Lipiodols
Lipiodol Ultrafluides (Guerbet Llc.) is a contrast agent based
on a mixture of ethyl esters of iodinated poppy seed oil that was
invented in 1901 and is indicated for use in lympangiography.
It has been used off label for many years to create viscous
emulsions of chemotherapy for treatment of hepatocellular
carcinoma, whereby the high viscosity causes reduction of
blood flow in the tumour and minimises drug wash-out and
hence could be classed as a transient liquid embolic agent.
The ethiodised oil is often mixed with the anticancer agent
doxorubicin or combinations of multiple chemotherapeutic
agents,38 followed by a subsequent embolisation of the feeding
tumour vessels performed using particles or microspheres in
order to permanently block the blood flow; this procedure is
termed conventional Trans-Arterial Chemo-Embolisation (cTACE).
Embolisation by combination of Lipiodols with other embolic
devices has been demonstrated to improve tumour response rates
to treatment versus just Lipiodol emulsion alone.39
The contrast agent provides a temporary embolic effect in
larger arteries40 but ultimately accumulates in hypervascularised
tumours as there is nomechanism for its removal due to the lack
of Kuppfer cells in tumour tissue.41 The retention of Lipiodols
within tumours is readily imaged under X-ray based methods
and is beneficial to the physician as it provides an indication
that the tumour has been successfully targeted.5 The treatment
of HCC by cTACE is performed in a set of at least two sequential
cTACE procedures with significant response often observed as
tumour necrosis by the second treatment.42
3. Emerging liquid embolics
Potential materials for use as liquid embolics can be spilt into
3 main types; polymerising, precipitating and phase transitioning.
Polymerising systems contain monomers or macro-monomers in
a carrier solution which polymerise upon contact with a suitable
initiator. The initiator can be mixed prior to the delivery of the
polymerising embolic allowing these materials to gel over a
predictable and predetermined time. Therefore, when using
polymerising systems premixed with an initiator, delivery must
be carried out within a limited time-frame in order to provide
effective embolisation and avoid microcatheter blocking and
entrapment. An alternative to this is to deliver polymerising
system via a dual-lumen microcatheter to ensure the reacting
components are kept separate during delivery until mixing at
the tip-section of the microcatheter. This delivery method relies
on a rapid rate of reaction to prevent wash-out of the embolic
material by the blood flow before gelation has occurred and
specialist catheter construction which can be expensive andmay
hinder the trackability of the catheter, limiting its ability to
navigate close to the target site.
Precipitating systems are administered as a polymer dis-
solved in a low toxicity and biocompatible carrier solvent. On
contact with a precipitation stimulant, such as non-solvent of
aqueous conditions or salt present within the blood, precipita-
tion of the previously dissolved polymer chains occurs to form a
gel in situ. Following gelation, the carrier solvent diffuses away
and generally aqueous-based media from the blood replaces it
within the polymer matrix. Precipitating polymers offer the
advantage that they form gels only when in contact with
precipitating stimulus present within physiological fluids and
therefore avoid the problem of gelation within the micro-
catheter which poses the risk of microcatheter blockage. This
allows delivery to be paused during the embolisation procedure
in order to prevent escape of material into non-target vessels
and allow more control. There are some disadvantages asso-
ciated with precipitating liquid embolics in that if the onset of
precipitation is not fast enough, the blood flow through the
vessel can result in wash-out leading to local or systemic toxicity
as a result of the free polymer. Also, a suitable carrier solvent
must be selected in order to avoid any toxic effects on injection
into the vasculature.
In addition to polymerising and precipitating systems, poly-
mers which undergo a sol–gel phase transition in response to
external stimuli have also been demonstrated to be useful in
the area of therapeutic embolisation. These materials respond
Fig. 5 Beam hardening and streak artefact (indicated by white arrow)
observed with Onyxs in the right hepatic artery by contrast enhanced axial
CT. Reproduced from Clin. Radiol., 2015, 70, 326–32.37
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to their surrounding environment due to changes in para-
meters such as temperature, pH, ion concentrations or electric
fields. Hence, phase transitioning polymers can be selected
which respond to physiological parameters such as body tem-
perature, blood pH or the salt concentrations in blood. Phase
transitioning systems can be designed to gel under conditions
similar to those experienced in an embolisation procedure such
as the change in temperature of the injected liquid from room
temperature to body temperature as its injected through the
microcatheter or the contact with blood and the change in
pH and ionic strength as the liquid exits the microcatheter at
the delivery site. There is a limitation for phase transitioning
materials that are solely thermo-responsive and gel at tempera-
tures around that of body temperature. This is due to the long
lengths of microcatheters used (typically 100–150 cm in length)
which can culminate in the injected liquid solution reaching
body temperature as it travels along the length of the micro-
catheter. This will likely result in microcatheter blockage if the
phase transition occurs before exiting the microcatheter.
3.1. Polymerising formulations
3.1.1 Instylla hydrogel embolic system. Instylla’s Hydrogel
Embolic System (Instylla – Incept Inc.) is a polyethylene glycol-
based system which polymerises in situ on mixing with an
initiator. The two components are injected from separate syringes
and flow down a dual lumen arrangement in the microcatheter,
formed by inserting a narrow inner tube within the microcather
lumen that finishes short of the microcatheter tip to allow a short
mixing zone. The low viscosity liquid undergoes rapid gelation to
form an embolic gel within the vasculature. The polymeric
material is not radiopaque, hence the material must be mixed
with contrast agent prior to delivery to monitor the injection.
The product has been tested in animal models in which high
vascular penetration was observed likely due to the low viscosity
of the liquid embolic. The liquid embolic system has been
tested using a range of microcatheters, including balloon
microcatheters, and alongside coil embolisation treatments.
Successful polymerisation of the gel was also observed in high
flow rate tests of 150 mL min1. Due to the successes demon-
strated in early testing of the liquid embolic system, further
in vitro and in vivo testing of Instylla’s Hydrogel Embolic System
is currently being performed.43
3.1.2 PPODA-QT. Vernon et al reported on a polymerising
system used in the filling of aneurysms in a swine model which
is composed of poly(propylene glycol)diacrylate (PPODA) that
is mixed with pentaerythritol tetrakis(3-mercaptopropionate)
(QT).44 The gelling solution is formulated with a catalytic
amount of hydroxide (HO) that deprotonates the QT thiol
group which then undertakes nucleophilic attack of the PPODA
acrylate group in a Michael-type addition reaction (Fig. 6). The
rate of gelation can be controlled by changing the pH but
injection over a 1–2 minute timeframe was reported to take
around 10 minutes.
3.2. Precipitating formulations
3.2.1 Squidt/Squid Perit. Squidt and Squid Perit (Emboflu,
Switzerland) are similar to Onyxs in that they are precipitating
liquid embolics composed of an EVA copolymer in a DMSO
suspension withmicronised tantalum powder. Squidt is indicated
for neuro applications and Squid Perit for peripheral use. In both
Squidt formulations a smaller grain size of tantalum powder is
used which has a slower rate of sedimentation in comparison
to Onyxs (Fig. 7).45 This provides longer working times of the
material due to its ability to retain homogeneous suspension over
a longer time frame which is particularly useful when using
prolonged injection times. Squidt is marketed in a range of
formulations including Squidt 12 and Squidt 18 which have
viscosities of 12 mPa s and 18 mPa s, respectively. This allows the
appropriate viscosity to be selected depending on the desired
clinical outcome, for example the lower viscosity Squidt 12 is
ideal for achieving deeper penetration into the vasculature often
required with the treatment of AVMs. Whereas, Squidt 18 is better
Fig. 6 Components & reaction scheme for gelation of PPODA-QT.
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suited to the treatment of endoleaks where the higher viscosity
of Squidt 18 is better able to resist wash out by blood flow.
Squidt formulations are also available with 30% less tantalum
in the suspension, marketed as Squidt 12LD and Squidt
18LD.46 The lower amount of tantalum in the liquid embolic
formulation reduces the imaging artefact of streaking which is
often observed with Onyxs. Despite the improved properties
over the well-established Onyxs treatment, Squidt has not
found widespread use in clinic likely due to its high cost and
requirement of DMSO compatible microcatheters.
3.2.2 Precipitating hydrophobic injectable liquid (PHILs).
The precipitating hydrophobic injectable liquid PHILs (Micro-
Vention (Terumo Corp)) is indicated for the embolisation of the
peripheral and neurovasculature, including AVMs and hyper-
vascular tumours.47–49 The liquid embolic is delivered using
DMSO as the carrier solvent which on mixing with blood
diffuses away as the polymeric material precipitates out of
solution on contact with the aqueous environment within
the vasculature to form a solid embolus. The polymer is based
on a 2,4,6-triidophenol-lactide-lactide-co-glycolic acrylate and
hydroxyethyl-methacrylate (HEMA) (2 : 1 monomer ratio) copo-
lymer which is non-adhesive in nature so avoids adhesion to
the microcatheter during delivery (Fig. 8). Again, due to the
DMSO carrier solvent used in the formulation, PHILs must be
used with specialist DMSO compatible connectors and micro-
catheters, similar to embolisation using Onyxs or Squidt. The
radiopacifying agent iodine is covalently bound to the polymer,
hence no pre-mixing of materials is required to achieve a
homogeneous suspension before delivery as is the case for
tantalum based radiopacifying agents and again, less streak
artefacts in imaging has been noted.50 Therefore, PHILs is
supplied in pre-loaded syringes which reduces the overall
procedural time. It is also marketed in a range of viscosities
(25, 30 and 35 wt% concentrations giving 16, 36 and 72 mPa s
solution viscosities) allowing the appropriate viscosity to be
selected for individual treatments depending on the desired
level of vascular penetration and flow rate scenarios.
It has been demonstrated that PHILs precipitates with a
greater volume of precipitate formed per mL of liquid embolic
injection than Onyxs,52 thereby requiring a reduced volume of
liquid embolic in the embolisation process potentially reducing
materials cost. In a study of AVM treatment followed by
resection, no major microcatheter blockages were reported
during use and histological analysis of the PHIL material in
the tissues showed it to be quite different to Onyx, being
more brittle and less pliable in nature and eliciting a greater
inflammatory reaction in the surrounding tissue.50
3.2.3 Iodinated polyvinyl alcohol (I-PVAL). A precipitating
liquid embolic based upon iodinated polyvinyl alcohol (I-PVAL)
dissolved in N-methyl pyrrolidone (NMP) was reported in the
literature some years ago and evaluated in a porcine model of
wide-necked aneurysms.53 The material proved safe and effec-
tive with good visibility but only more recently has it been
commercialised by Antia Therapeutics AG. This precipitating
liquid embolic known as Easyxt, is still composed of PVAL
(also known as PVA or PVOH) with iodine containing moieties
covalently bound to the polymer backbone through ether
Fig. 7 X-ray images showing the longer tantalum suspension time (as
indicated by the white arrow) of Squidt 18 (A) in comparison to Onyxs 18
(B) 15 minutes after agitation (image from Emboflu promotional brochure
for Squidt).
Fig. 8 Chemical structure of the PHIL copolymer – The arrangement of glycolide/lactide/lactide units in the iodinated monomer is likely randomised on
the PHIL product. Ratio Monomer :HEMA is estimated to be 2 : 1.51
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linkages (Fig. 9).54 However now, as with Onyxs, Squidt and
PHILs, the product is formulated in DMSO as the carrier
solvent which diffuses away from the embolus as the polymer
precipitates out of solution on contact with the aqueous con-
ditions of blood. The exact reason for the developers switching
carrier solvent is unknown but may be as a result of a simpler
regulatory pathway to product approval. As with the other
products, this requires the use of DMSO compatible micro-
catheters to prevent the deterioration of the microcatheters
by the solvent. The inherent radiopacity imparted by the
covalently bound iodine allows the liquid embolic to be clearly
visualised by computed tomography (CT) imaging without
the shading and beam-hardening artefacts observed with the
tantalum radiopacifying agent used with Onyxs.55 Also, the
covalent binding of the radiopaque group alleviates the need to
pre-mix the liquid embolic with a radiopacifying agent prior to
delivery as the radiopaque materials are supplied in a ready
to use solution in DMSO. Easyxt has been developed for the
embolisation of hypervascular lesions including tumours and
AVMs. The liquid embolic is currently undergoing clinical trials
but early data has demonstrated effective embolisation with
homogeneous visibility under CT imaging.55–57
3.2.4 Eudragit-E (poly(MM-co-BM-co-DMAEMA)). Tamura
et al. reported on the endovascular embolisation of brain AVMs
using a copolymer of methyl methacrylate, butyl methacrylate
and dimethylaminoethyl methacrylate (poly(MM-co-BM-co-
DMAEMA), Fig. 10) known as Eudragit-E and dissolved in a
carrier mixture of 50 : 50 ethanol and iopamidol contrast agent.58
The polymer itself has a history of medical use as a tablet coating
for taste masking and is one of a family of amorphous non-
biodegradable, non-absorbable, non-toxic materials marketed
under the generic Eudragit name (Evonik Industries, Germany).
Prior to delivery, the microcatheter needs to be first flushed with
ethanol to prevent premature precipitation and occlusion of the
lumen. Injection into the swine Rete mirabilia (a common
model for AVM evaluation) and subsequent histopathology has
revealed a tissue reaction similar to nBCA with inflammation
and thrombosis accompanied by extensive endothelial damage.59
This is likely to be largely due to the toxicity of the ethanol carrier,
which is itself a sclerosant. There was not however, any evidence
of haemorrhage or extravasation of the material. Radiopacity is
only transient, provided by the iopamidol contrast agent which
eventually diffuses out of the precipitated polymer mass. Despite
these promising findings, there is little in the literature since
these reports to suggest the company is actively developing this as
a liquid embolic commercial offering.
3.3. Phase transitioning
3.3.1 GPX. GPX (Fluidx Medical Technology) is a bio-
mimetic aqueous based liquid embolic system. The liquid
embolic is based on the liquid glue secreted by sandcastle
worms to create tubular structures using grains of sand.60,61
Using the same principal as the sandcastle worms, GPX
consists of polyelectrolyte complexes which are stabilised in
aqueous solutions of high ionic strength (Fig. 11). The formula-
tion consists of protamine sulfate (from salmon sperm) and
sodium inositol hexaphosphate (phytic acid), is rendered radio-
paque by addition of tantalum powder particles (1.5 mm in size)
and maintained in an un-coacervated state by the addition
of 1.2 M sodium chloride. The stabilised solution can be
delivered through the narrow lumens of microcatheters used
in embolisation procedures. On exiting the microcatheter at the
injection site, the polyelectrolyte complexes become destabi-
lised due to the reduction of the ionic strength to physiological
strength through blood dilution. This causes the polyelectrolyte
complexes to aggregate to form a gelled embolus within the
Fig. 9 Putative structure of Easyxt copolymer – The product is likely be either a mixture of poly(vinyl-4-mono-iodo benzyl ether) MIB-PVAL (A) &
poly(vinyl-2,3,5-triiodo-benzyl ether) TIB-PVAL (B), or copolymer C.
Fig. 10 Chemical structure of Eudragit E.
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vasculature with rapid gelation exhibited within seconds. Two
different viscosity formulation are being proposed which have a
toothpaste-like delivery and control. The resulting embolic
mass is non-cytotoxic, non-haemolytic, and non-inflammatory.
Despite the fact the material is based upon a glue-like substance,
the embolus formed was also found to be non-adhesive in nature
to the microcatheter used to deliver the embolic material.
Embolisation using GPX has been performed in rabbit renal
arteries demonstrating a high level of vascular penetration and
complete occlusion of the kidney.62
3.3.2 Calcium alginate. Calcium alginate is a widely used
material in medical applications63 and its use as a liquid
embolic agent was reported some years ago.64 Alginate is a
copolymer composed of units of mannuronic and guluronic
acid groups that are ionically crosslinked by divalent cations
such as Ca2+ (Fig. 12). A concentric tube microcatheter design
was used in the evaluation of this system in an animal model of
side-wall aneurysms. Delivery was feasible with no off-target
fragmentation and analysis at 30 and 90 days showed the
alginate allowed for tissue overgrowth of the aneurysm opening
with moderate fibrous tissue formation.64 In a later study by
other investigators, co-delivery of alginate plus iohexol contrast
agent in one stream and calcium ions in the other, with mixing
at the exit point of the microcatheter, resulted in a string-like
gel (termed Embogel).65 This was shown to effectively fill fusi-
form and saccular aneurysm models when used in conjunction
with a AAA stent. The need for specialist microcatheters with
reduced trackability limits the locations that can be targeted
and adds cost to the procedure and hence has hindered the
continued development of alginate-based systems. This has led
researchers to attempt to modify the properties by ad-mixing
with other components and in one report alginate, calcium,
Poloxamer 407, hydroxymethylcellulose and iodixanol to add
radiopacity were formulated in order to produce a liquid embolic
composition that had thermosensitive properties, transitioning
between flowing sol to gel at body temperature66 and proved
feasible to deliver and embolise rabbit renal arteries.
3.3.3 Temperature sensitive hydrogel systems. A phase
transitioning injectable material has been developed using a
Silk Elastin Protein Polymer (SELP) (Fig. 13). Phase transition of
the polymeric material occurs in response to temperature
undergoing a sol–gel transition on an increase in temperature
from room temperature to body temperature at 37 1C.68 Feasibility
of the material as an injectable material has been demonstrated
using an in vitro and in vivo model.69,70 The product is currently
under further investigation for use as a therapeutic gene
delivery system.
A temperature sensitive poly(N-isopropylacrylamide-co-butyl
methacrylate) (PNIPAM-BM, or PIB) nanogel-forming material
has also been described for use as a liquid embolic agent,71
based upon the widely known phase transition of PNIPAM from
hydrophilic to hydrophobic in nature above its lower critical
solution temperature (LCST). This system has the advantage of
not requiring an organic solvent being aqueous-based and is
forms a non-adhesive hydrogel that does not stick to the
catheter. It has no intrinsic radiopacity and required mixing
with iohexol contrast agent in order to impart temporary radio-
pacity. Rapid delivery (40.1 mL s1) was required to ensure
distribution to the more peripheral vessels before gelation
occurred and indeed, slow delivery resulted in proximal occlu-
sion with the risk of microcatheter blockage if the injection was
stopped making the procedure impractical.
A material based upon chitosan/b-glycerophosphate has been
described, with similar properties to PIB in that it phase-
transitions at room temperature to form a non-adhesive,
Fig. 11 Schematic of the complexation of a polyelectrolyte from a poly-
anion and polycation.
Fig. 12 Structure and crosslinking mechanism for sodium alginate.
Reproduced from Carbohydr. Polym., 2015, 131, 57–64.67
Fig. 13 Amino acid composition of a silk elastin protein polymer (SELP-47 K).
Image adapted from Biomater., 2015, 57, 142–52.
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non-toxic hydrogel at 37 1C. This material was evaluated in a
rabbit renal artery model72 and in the rete mirabile in swine.73
Interestingly, these materials have been formulated with
indocyanine green and evaluated for potential intraoperative
fluorescent imaging and local therapy of hepatocellular
carcinoma.74 Whilst the dye did not affect the gelation rate,
the gel transition temperature was above 4 1C making the
handling and avoidance of premature gelling of this material
very difficult.
3.3.4 PuraMatrixt. PuraMatrixt (3D Matrix Co., Ltd,
Tokyon, Japan) is based upon a peptide with 16 amino acids
comprised of arginine, aspartate and alanine repeating
units (RADARADARADARADA, RADA16-I). Although originally
developed as a cell scaffold material, it has been formulated at
2.5 wt% in aqueous media mixed with iodinated contrast agent
to impart radiopacity as a proposed liquid embolic agent.75
This peptide sequence has an alternating hydrophobic/charged
motif that promotes b-strand formation and self-assembly into
a nanofiber-based hydrogel material.76 Evaluation in an embo-
lisation setting confirmed the ability of the material to gel and
induce cessation of blood flow in target vessels. Pathological
analysis revealed an ability to reach distal locations due to its
non-adhesive nature and little inflammation in the vessel and
surrounding tissues.
3.3.5 Shear-thinning biomaterials. Shear-thinning bio-
materials (STB) are an attractive approach to liquid embolics
as their rheological properties are such that their viscosity
drops as it is sheared by injection through the narrow lumen
of a microcatheter. Once the shear stress is removed as it exits
the catheter and enters the less confined environment of the
blood vessel, the material returns to its gel state and form an
embolus in situ. Currently under investigation as a liquid
embolic alternative is a STB based on a nanocomposite hydro-
gel composed of gelatin and silicate nanoplatelets (Fig. 14).70,77
This STB demonstrated injectability through a range of micro-
catheters and needles and formed a sufficient embolus that
could withstand physiological pressures without displacement
in the vasculature. The application of shear disrupts charge
interactions between the gelatin and silicate particles, dropping
the viscosity as the apparent molecular weight decreases, which
are restored again to reinforce the gel once the shear is removed.
The aqueous nature of the system alleviates the need to use
DMSO compatible microcatheters as required by a number
of liquid embolics. However, the material used in the GPX
formulation is not inherently radiopaque so would need to be
delivered alongside a contrast agent to enable visualisation of
the embolisation procedure. Liquid contrast agent would likely
alter the rate of gelation of the liquid embolic system and
particulate tantalum may interfere with the gelatin-silicate
interactions, hence further testing of the STB is still required.
4. Conclusions and future
perspectives
There are numerous liquid embolics currently under develop-
ment aiming to alleviate some of the current issues faced with
commercially available liquid embolics and provide additional
tools for use in therapeutic embolisation. There are however, a
number of prerequisites which must be fulfilled in order to
demonstrate improved properties and clinical benefit over the
currently established agents already available on the market.
These properties include reduced streak artefact on imaging,
appropriate gelation triggers to avoid catheter blockage and
suitable viscosities to occlude at the desired location under
different flow regimes within the vasculature and control over
the delivery without risk of fragmentation and stringing to off-
target sites. Some desirable attributes for the next generation of
liquid embolics would be the possession of inherent radio-
pacity to avoid the need to pre-mix materials prior to injection
and systems which are free of solvent to reduce the risk of toxic
side effects often associated with the use of solvent and the
need to use solvent-compatible microcatheters and delivery
accessories. These properties are currently unmet needs and
the next generation of liquid embolics systems reviewed herein
are likely to address these to a greater or lesser extent.
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